FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163717145> ?p ?o ?g. }

• W2163717145 endingPage "e217" @default.
• W2163717145 startingPage "e211" @default.
• W2163717145 abstract "Purpose To determine the predictive risk factors for Grade 2 or worse rectal bleeding after high-dose-rate brachytherapy (HDR-BT) combined with hypofractionated external-beam radiotherapy (EBRT) for prostate cancer using dose–volume histogram analysis. Methods and Materials The records of 216 patients treated with HDR-BT combined with EBRT were analyzed. The treatment protocols for HDR-BT were 5 Gy × five times in 3 days or 7 Gy × three, 10.5 Gy × two, or 9 Gy × two in 2 days. The EBRT doses ranged from 45 to 51 Gy with a fractional dose of 3 Gy. Results In 20 patients Grade 2 or worse rectal bleeding developed, and the cumulative incidence rate was 9% at 5 years. By converting the HDR-BT and EBRT radiation doses into biologic effective doses (BED), the BED3 at rectal volumes of 5% and 10% in the patients who experienced bleeding were significantly higher than those in the remaining 196 patients. Univariate analysis showed that a higher rectal BED3–5% and the use of fewer needles in brachytherapy were correlated with the incidence of bleeding, but BED3–5% was found to be the only significant factor on multivariate analysis. Conclusions The radiation dose delivered to small rectal lesions as 5% is important for predicting Grade 2 or worse rectal bleeding after HDR-BT combined with EBRT for prostate cancer. To determine the predictive risk factors for Grade 2 or worse rectal bleeding after high-dose-rate brachytherapy (HDR-BT) combined with hypofractionated external-beam radiotherapy (EBRT) for prostate cancer using dose–volume histogram analysis. The records of 216 patients treated with HDR-BT combined with EBRT were analyzed. The treatment protocols for HDR-BT were 5 Gy × five times in 3 days or 7 Gy × three, 10.5 Gy × two, or 9 Gy × two in 2 days. The EBRT doses ranged from 45 to 51 Gy with a fractional dose of 3 Gy. In 20 patients Grade 2 or worse rectal bleeding developed, and the cumulative incidence rate was 9% at 5 years. By converting the HDR-BT and EBRT radiation doses into biologic effective doses (BED), the BED3 at rectal volumes of 5% and 10% in the patients who experienced bleeding were significantly higher than those in the remaining 196 patients. Univariate analysis showed that a higher rectal BED3–5% and the use of fewer needles in brachytherapy were correlated with the incidence of bleeding, but BED3–5% was found to be the only significant factor on multivariate analysis. The radiation dose delivered to small rectal lesions as 5% is important for predicting Grade 2 or worse rectal bleeding after HDR-BT combined with EBRT for prostate cancer." @default.
• W2163717145 created "2016-06-24" @default.
• W2163717145 creator A5003938029 @default.
• W2163717145 creator A5007728254 @default.
• W2163717145 creator A5016895265 @default.
• W2163717145 creator A5017340969 @default.
• W2163717145 creator A5020294120 @default.
• W2163717145 creator A5023360717 @default.
• W2163717145 creator A5024701320 @default.
• W2163717145 creator A5036226748 @default.
• W2163717145 creator A5049584975 @default.
• W2163717145 creator A5070071795 @default.
• W2163717145 creator A5074150160 @default.
• W2163717145 creator A5081056035 @default.
• W2163717145 date "2012-02-01" @default.
• W2163717145 modified "2023-10-04" @default.
• W2163717145 title "Rectal Bleeding After High-Dose-Rate Brachytherapy Combined With Hypofractionated External-Beam Radiotherapy for Localized Prostate Cancer: The Relationship Between Dose-Volume Histogram Parameters and the Occurrence Rate" @default.
• W2163717145 cites W1868732334 @default.
• W2163717145 cites W1964414726 @default.
• W2163717145 cites W1978242635 @default.
• W2163717145 cites W1978906140 @default.
• W2163717145 cites W1979914233 @default.
• W2163717145 cites W1990510898 @default.
• W2163717145 cites W1996236608 @default.
• W2163717145 cites W1996809772 @default.
• W2163717145 cites W2004055070 @default.
• W2163717145 cites W2011939278 @default.
• W2163717145 cites W2020242089 @default.
• W2163717145 cites W2020538090 @default.
• W2163717145 cites W2033187933 @default.
• W2163717145 cites W2039139527 @default.
• W2163717145 cites W2061444197 @default.
• W2163717145 cites W2071238711 @default.
• W2163717145 cites W2082330666 @default.
• W2163717145 cites W2094599429 @default.
• W2163717145 cites W2097228107 @default.
• W2163717145 cites W2098771816 @default.
• W2163717145 cites W2104631398 @default.
• W2163717145 cites W2104874527 @default.
• W2163717145 cites W2112125246 @default.
• W2163717145 cites W2114039855 @default.
• W2163717145 cites W2115675646 @default.
• W2163717145 cites W2124537997 @default.
• W2163717145 cites W2125272830 @default.
• W2163717145 cites W2129584252 @default.
• W2163717145 cites W2130514725 @default.
• W2163717145 cites W2130574795 @default.
• W2163717145 cites W2139914113 @default.
• W2163717145 cites W2141952239 @default.
• W2163717145 cites W2142438802 @default.
• W2163717145 cites W2146780512 @default.
• W2163717145 cites W2151819325 @default.
• W2163717145 cites W2157531509 @default.
• W2163717145 cites W2160406420 @default.
• W2163717145 cites W2167423604 @default.
• W2163717145 cites W4293241248 @default.
• W2163717145 doi "https://doi.org/10.1016/j.ijrobp.2011.03.041" @default.
• W2163717145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21620579" @default.
• W2163717145 hasPublicationYear "2012" @default.
• W2163717145 type Work @default.
• W2163717145 sameAs 2163717145 @default.
• W2163717145 citedByCount "13" @default.
• W2163717145 countsByYear W21637171452013 @default.
• W2163717145 countsByYear W21637171452014 @default.
• W2163717145 countsByYear W21637171452015 @default.
• W2163717145 countsByYear W21637171452016 @default.
• W2163717145 countsByYear W21637171452017 @default.
• W2163717145 countsByYear W21637171452018 @default.
• W2163717145 countsByYear W21637171452020 @default.
• W2163717145 countsByYear W21637171452021 @default.
• W2163717145 crossrefType "journal-article" @default.
• W2163717145 hasAuthorship W2163717145A5003938029 @default.
• W2163717145 hasAuthorship W2163717145A5007728254 @default.
• W2163717145 hasAuthorship W2163717145A5016895265 @default.
• W2163717145 hasAuthorship W2163717145A5017340969 @default.
• W2163717145 hasAuthorship W2163717145A5020294120 @default.
• W2163717145 hasAuthorship W2163717145A5023360717 @default.
• W2163717145 hasAuthorship W2163717145A5024701320 @default.
• W2163717145 hasAuthorship W2163717145A5036226748 @default.
• W2163717145 hasAuthorship W2163717145A5049584975 @default.
• W2163717145 hasAuthorship W2163717145A5070071795 @default.
• W2163717145 hasAuthorship W2163717145A5074150160 @default.
• W2163717145 hasAuthorship W2163717145A5081056035 @default.
• W2163717145 hasConcept C121608353 @default.
• W2163717145 hasConcept C126322002 @default.
• W2163717145 hasConcept C126838900 @default.
• W2163717145 hasConcept C126894567 @default.
• W2163717145 hasConcept C144301174 @default.
• W2163717145 hasConcept C201645570 @default.
• W2163717145 hasConcept C2775908122 @default.
• W2163717145 hasConcept C2776235491 @default.
• W2163717145 hasConcept C2777416452 @default.
• W2163717145 hasConcept C2780192828 @default.
• W2163717145 hasConcept C2780198649 @default.
• W2163717145 hasConcept C2989005 @default.
• W2163717145 hasConcept C38180746 @default.
• W2163717145 hasConcept C509974204 @default.
• W2163717145 hasConcept C526805850 @default.

• next